All tissue culture reagents were from Invitrogen (Carlsbad, CA, USA), unless otherwise specified. Fetal bovine serum (FBS) was from Gemini Bio-products (Woodland, CA, USA). Aβ25–35, Aβ35–25, Aβ1–42, and Aβ42–1 peptides, as well as nitro-L-arginine methyl ester (L-NAME), were from Sigma-Aldrich (St. Louis, MO, USA). Monoclonal and polyclonal anti-eNOS and anti-HSP90 antibodies were from BD-Transduction Laboratories (San Diego, CA, USA). The polyclonal antibody for phospho-eNOS (Ser 1179) was from Invitrogen (Grand Island, NY, USA). Polyclonal and monoclonal antibodies for anti-Akt and phospho-Akt (Ser473) were purchased from Cell Signaling (Danvers, MA, USA). Protein A/G agarose beads were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The ECL chemiluminescence detection assay as well as the peroxidase-conjugated anti-mouse/anti-rabbit IgG were from Amersham Biosciences (Piscataway, NJ, USA). The cGMP enzyme-immunoassay kit was from Cayman Chemical Co. (Ann Arbor, MI, USA). The blots were reprobed after stripping using a stripping solution from Pierce (Rockford, IL, USA).
Aβ35 25
Manufactured by Merck Group
Sourced in United States
Aβ35–25 is a synthetic peptide fragment derived from the amyloid-beta (Aβ) protein. It is commonly used in research applications as a tool for studying the structure and function of the Aβ protein.
Automatically generated - may contain errors
Lab products found in correlation
Aβ25 35, by Merck Group (3 mentions)
Nitro l arginine methyl ester l name, by Merck Group (1 mentions)
Cgmp enzyme immunoassay kit, by Cayman Chemical (1 mentions)
Aβ1 42, by Merck Group (1 mentions)
Fetal bovine serum (fbs), by Gemini Bio (1 mentions)
Protein a g agarose bead, by Santa Cruz Biotechnology (1 mentions)
3 protocols using aβ35 25
1
Investigating Amyloid-Beta Pathways
2
Rat Model of Alzheimer's Disease
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A rat model of AD was established by microinjecting with a microsyringe (5 μL per side, 1 μL/min) aggregated Aβ25–35 (Sigma-Aldrich, St. Louis, MO, USA) into the bilateral brain ventricles of rats. After injections, the needle was left in place for 5 minutes before it was slowly extracted. The skin incision was disinfected with complex iodine and sutured. All operations were performed under sterile conditions.
Rats in the sham-operated group (sham group) were treated with the same method and injected with the same amount of Aβ35–25 (Sigma-Aldrich). Both Aβ25–35 and Aβ35–25 were dissolved in sterile distilled water at a concentration of 2 mg/mL and incubated at 37°C for 1 week to form aggregations (Teng et al., 2014).
The rats were randomly divided into the five following groups (n = 7 per group): sham group (Aβ25–35 intracerebroventricular injection + distilled water), AD model group (Aβ25–35 intracerebroventricular injection + distilled water), low-dose BTD group (Aβ25–35 intracerebroventricular injection + low-dose BTD), moderate-dose BTD group (Aβ25–35 intracerebroventricular injection + moderate-dose BTD) and high-dose BTD group (Aβ25–35 intracerebroventricular injection + high-dose BTD).
Rats in the sham-operated group (sham group) were treated with the same method and injected with the same amount of Aβ35–25 (Sigma-Aldrich). Both Aβ25–35 and Aβ35–25 were dissolved in sterile distilled water at a concentration of 2 mg/mL and incubated at 37°C for 1 week to form aggregations (Teng et al., 2014).
The rats were randomly divided into the five following groups (n = 7 per group): sham group (Aβ25–35 intracerebroventricular injection + distilled water), AD model group (Aβ25–35 intracerebroventricular injection + distilled water), low-dose BTD group (Aβ25–35 intracerebroventricular injection + low-dose BTD), moderate-dose BTD group (Aβ25–35 intracerebroventricular injection + moderate-dose BTD) and high-dose BTD group (Aβ25–35 intracerebroventricular injection + high-dose BTD).
3
Amyloid-Beta Peptide Aggregation and Toxicity
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Aβ25-35 and a control peptide Aβ35-25 are from Sigma. Before use, 2 mM Aβ25-35 stock solution was prepared by water and aged in a humidified chamber at 37°C for 5 days to obtain aggregates of Aβ peptides. The control peptide Aβ35-25 followed the same procedure. After 12 h infection of adenovirus, the cells were treated with 20 μM Aβ25-35 or Aβ35-25 by directly adding to the medium.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!